Aakash Desai· @ADesaiMD · X·· 17 小时前评分70
正文 · 原文
#ESMO26 Phase 1 Temab-A (c-Met ADC), NSQ NSCLC @abbvie
➡️ EGFR WT (n=48): ORR 50%, mPFS 6.8, mOS 13.8 mo
➡️ EGFRm (n=41): ORR 63%, mPFS 10.9, mOS 16.2 mo
➡️ WT c-Met 3+ ≥10%: mOS 25.2 vs 9.7 mo
Small changes to payload, big impact?
@LungCancerRx @OncoAlert @oncodaily
168 浏览 · 4 赞 · 2 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Aakash Desai · x.com